Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3413719 | 1.00 | MAPT (0.64) | MAPTKMT2AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL3413101 | 1.00 | MAPT (0.64) | MAPTKMT2AALDH1A1GAASMN1; SMN2 | |
| SCHEMBL12056319 | 0.84 | EPHX2 (0.49) | MAPTKMT2AALDH1A1GAAPOLB | |
| SCHEMBL12056320 | 0.83 | EPHX2 (0.51) | MAPTKMT2AGAAPOLBMAPK1 | |
| SCHEMBL1399585 | 0.83 | MAPT (0.52) | MAPTKMT2AALDH1A1GAAPOLB | |
| SCHEMBL18703105 | 0.83 | MAPT (0.51) | MAPTKMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL3412798 | 0.82 | POLB (0.53) | KMT2AALDH1A1GAASMN1; SMN2POLB | |
| SCHEMBL3542997 | 0.82 | POLB (0.53) | KMT2AALDH1A1GAASMN1; SMN2POLB | |
| SCHEMBL3412804 | 0.82 | POLB (0.53) | KMT2AALDH1A1GAASMN1; SMN2POLB | |
| SCHEMBL3933617 | 0.82 | EPHX2 (0.52) | KMT2AGAAMEN1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084478-B2 | Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase | ASSTRAZENECA AB (SE) | 2011-12-27 | — | — | US | disclosed |
| EP-2041100-B1 | SUBSTITUTED 5- PHENYLAMINO- 1, 3, 4-OXADIAZ0L-2-YLCARBONYLAMINO-4-PHENOXY-CYCLOHEXANE CARBOXYLIC ACID AS INHIBITORS OF ACETYL COENZYME A DIACYLGLYCEROL ACYLTRANSFERASE | ASTRAZENECA AB (SE) | 2010-12-22 | — | — | EP | disclosed |
| US-20090275620-A1 | SUBSTITUTED 5- PHENYLAMINO- 1, 3, 4-OXADIAZOL-2-YLCARBONYLAMINO-4-PHENOXY-CYCLOHEXANE CARBOXYLIC ACID AS INHIBITORS OF ACETYL COENZYME A DIACYLGLYCEROL ACYLTRANSFERASE | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275620-A1 | SUBSTITUTED 5- PHENYLAMINO- 1, 3, 4-OXADIAZOL-2-YLCARBONYLAMINO-4-PHENOXY-CYCLOHEXANE CARBOXYLIC ACID AS INHIBITORS OF ACETYL COENZYME A DIACYLGLYCEROL ACYLTRANSFERASE | ACAT2, ACAT1, DGAT1 | MAPT 3051/4885KMT2A 826/4885ALDH1A1 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.